Proven Results for the HeartMate 3 LVAD | Abbott
CARDIOVASCULAR
hamburger
HeartMate 3 LVAD Therapy

HeartMate 3 LVAD has long-term proven outcomes

The HeartMate 3™ LVAD has been proven to help people with heart failure feel better and live longer.

Median survival
exceeding
5 years1

Meaning that an
equal number of
people lived longer
than 5 years as the
number of people
who died in less
than 5 years.

Exceeding 5 years

58.4%
survival at
5 years1

Nearly 60% of
the patients enrolled
in the study were
alive after 5 years

Nearly 60%

Significant increase in six-minute walk distance.2

The six-minute walk test is a common way to test for your ability to perform daily physical activities. Patients who received the HeartMate 3 LVAD had a significant improvement in six-minute walk distance.

Depiction of how far a person can walk on a football field. First icon demonstrating before HeartMate 3 LVAD therapy can walk 136m, and second icon demonstrating after HeartMate 3 LVAD therapy can walk 323m, which is over two times farther.

Risk and Complication Information

There can be serious complications associated with LVAD therapy. It is important to understand these risks and discuss them with your doctor.

Other than the risks normally associated with major surgery and having general anesthesia, the potential complications of having a HeartMate LVAD are listed here.

Low Risk Profile For Continous-Flow LVAD

Results based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.

HeartMate LVAD Information Center: 1-855-743-2786

Call our information center to find an LVAD clinic near you. Our LVAD clinic finder will connect you with an advanced heart failure care team in your area.

Call us Monday through Friday, 7 A.M. - 7 P.M. Central time

If you call outside of these times, please leave a message and your call will be returned the next business day.

Additional Information

These materials are not intended to replace your doctor’s advice or information. For any questions or concerns you may have regarding the medical procedures, devices and/or your personal health, please discuss these with your physician.

References

  1. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA. September 8, 2022. doi:10.1001/jama.2022.16197
  2. Schmitto JD, Shaw S, Garbade J, et al. Long-Term Results in Real World Patients Treated with HeartMate 3 LVAD for Advanced Heart Failure: Data from the ELEVATE Registry. European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting; October 8, 2022; Milan, Italy.
INDICATIONS, SAFETY & WARNINGS

MAT-2108555 v3.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.